Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Organisation › Details

Nouscom (Group)

Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom's proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Nouscom is currently advancing clinical development of its lead program, NOUS-209, an off-the-shelf cancer vaccine based on shared frame shift neoantigens. The Company continues to develop its product candidate, NOUS-PEV, a personalized cancer neoantigen- vaccine, which is expected to enter clinical studies in 2020. Nouscom is led by an experienced management team with deep roots in the pharma and biotech industry (Merck, Novartis, Lilly, Incyte and Okairos (acquired by GSK)), and are veterans in the field of viral vectored genetic vaccines. Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures. *


Period Start 2016-05-17 existent
Products Industry cancer vaccine
  Industry 2 drug development
Persons Person Udier-Blagovic, Marina (Nouscom 202002– CEO joined 201609 as COO before Versant Ventures + Novartis + McKinsey)
  Person 2 Nicosia, Alfredo (NousCom 201605–201905 CEO at NousCom Srl + Co-Founder before Okairos RETIRED 5/19)
Region Region Basel BS
  Country Switzerland
  Street 18 Bäumleingasse
  City 4051 Basel
  Tel +41-61-201-1831
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for »About Section«: Nouscom AG. (2/26/20). "Press Release: Nouscom Strengthens Its Management Team. Marina Udier, PhD Appointed as Chief Executive Officer and Patricia Delaite, MD Appointed as Chief Medical Officer". Basel.
Record changed: 2023-07-10


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Nouscom (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top